Aditya Birla SL Pharma & Healthcare Fund
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
Growthvine rating: 3/5 — ranked #40 of 87 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹33.60 (as of 2026-10-22) |
|---|
| AUM | ₹1,078 Cr |
|---|
| Expense ratio | 1.90% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dhaval Shah |
|---|
| Exit load | 1% for redemption within 30 days |
|---|
Performance & risk
| 5-year annualised return | 12.41% |
|---|
| Sharpe ratio | 0.82 |
|---|
| Standard deviation | 15.55% |
|---|
| Max drawdown | −21.38% |
|---|
| Alpha | -1.06 |
|---|
| Beta | 0.91 |
|---|
Over 5 years, captured 93.3% of NIFTY Pharma's upside and 93.7% of its downside.
Market cap allocation
| Large cap | 33.6% |
|---|
| Mid cap | 31.3% |
|---|
| Small cap | 35.1% |
|---|
Concentration
| Top 5 holdings | 35.2% |
|---|
| Top 10 holdings | 54.5% |
|---|
| Total holdings | 39 |
|---|
Top holdings
- Torrent Pharmaceuticals Ltd. — 9.3%
- Sun Pharmaceutical Industries Ltd. — 8.6%
- Apollo Hospitals Enterprises Ltd. — 6.4%
- Cipla Ltd. — 6.4%
- Aurobindo Pharma Ltd. — 4.5%
- Sai Life Sciences Limited — 4.5%
- Ajanta Pharma Ltd. — 4.3%
- Mankind Pharma Limited — 3.6%
- Dr. Lal Pathlabs Limited — 3.5%
- Abbott India Ltd. — 3.3%
Top sectors
- Pharma & Biotech — 74.9%
- Healthcare — 21.6%
- Cash — 2.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 9.5% | Q1 (Top) | #11 of 76 |
| 2025 | −4.3% | Q3 | #52 of 69 |
| 2024 | 35.8% | Q1 (Top) | #13 of 58 |
| 2023 | 37.7% | Q2 | #23 of 48 |
| 2022 | −12.7% | Q4 (Bottom) | #41 of 46 |